Viatris/$VTRS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Viatris
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.
- Ticker
- $VTRS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 30,000
- Headquarters
- Canonsburg, United States
- Website
- www.viatris.com
Viatris Metrics
BasicAdvanced
$24B
-
-$0.53
0.87
$0.48
2.28%
Price and volume
Market cap
$24B
Beta
0.87
52-week high
$21.10
52-week low
$10.15
Average daily volume
9.3M
Dividend rate
$0.48
Financial strength
Current ratio
1.552
Quick ratio
0.74
Long term debt to equity
0.858
Total debt to equity
0.973
Interest coverage (TTM)
3.39%
Profitability
EBITDA (TTM)
4,376.4
Gross margin (TTM)
41.13%
Net profit margin (TTM)
-4.13%
Operating margin (TTM)
10.88%
Effective tax rate (TTM)
-15.46%
Revenue per employee (TTM)
$490,000
Management effectiveness
Return on assets (TTM)
2.76%
Return on equity (TTM)
-4.21%
Valuation
Price to revenue (TTM)
1.652
Price to book
1.76
Price to tangible book (TTM)
-4.01
Price to free cash flow (TTM)
12.299
Free cash flow yield (TTM)
8.13%
Free cash flow per share (TTM)
1.712
Dividend yield (TTM)
2.28%
Forward dividend yield
2.28%
Growth
Revenue change (TTM)
4.27%
Earnings per share change (TTM)
-83.17%
3-year revenue growth (CAGR)
-1.62%
10-year revenue growth (CAGR)
3.64%
3-year earnings per share growth (CAGR)
-29.69%
10-year earnings per share growth (CAGR)
0.53%
What the Analysts think about Viatris
Analyst ratings (Buy, Hold, Sell) for Viatris stock.
Analyst projections of the future price of Viatris stock.
Bulls say / Bears say
Viatris raised the midpoint of its 2026 adjusted EPS guidance to $2.60, implying 8% operational growth year on year, and also lifted its EBITDA outlook. That suggests cost discipline and better earnings momentum even as revenue growth remains modest. (Viatris)
New launches and complex generics are gaining traction: North American sales grew 7% in the quarter, and Viatris expects about $450 million of new-product revenue for 2026. Recent approvals and launches, including RYZUMVI and WAKIX, add further opportunities to build sales. (Viatris)
The agreed Pacira acquisition would add established, patent-protected pain medicines EXPAREL and ZILRETTA, which generated about $746 million in revenue and $177 million in adjusted EBITDA over the year to June 2026. Those products could diversify Viatris beyond lower-margin generics, although the deal remains pending. (Viatris)
The Nashik plant is under an FDA Official Action Indicated classification and Viatris suspended production while it remediates the site. Supply constraints cost about $100 million of revenue in the third quarter, with a similar impact expected in the fourth quarter and production not expected to resume until 2027. (Viatris)
Revenue was flat in the third quarter as new-product sales were offset by supply problems and competition. Management also expects China’s hospital procurement changes to moderate growth, while competition and a potential 2027 loss of exclusivity for Amitiza in Japan add further pressure. (The Motley Fool)
Viatris reported a $325 million GAAP net loss in the third quarter, wider than the $128 million loss a year earlier. The company attributed the deterioration mainly to higher tax expense in jurisdictions where it could not recognise tax benefits, showing that adjusted earnings growth has not yet translated into stable reported profits. (Viatris)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
Viatris Financial Performance
Revenues and expenses
Viatris Earnings Performance
Company profitability
Upcoming events
Viatris News
AllArticlesVideos
Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX
Business Wire1 month ago
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pacira BioSciences, Inc. (PCRX)
Newsfile Corp1 month ago
Viatris to Buy Pacira BioSciences for $1.65 Billion
WSJ1 month ago
Funds containing Viatris
AllUSDEURGBP
Fund name | Fund size | $VTRS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 1.51% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 1.51% |
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.54% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $2.7B | 0.36% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $2.7B | 0.36% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.